Key Drivers
- Strong Liquidity
- Thin EBIT
- Interest Burden
AIAI Summary
NEOG is now a fragile turnaround with real operational traction and improving cash generation, but the stock still needs proof that thin EBIT and execution risks—especially in Animal Safety and manufacturing transitions—can translate into durable earnings before a full re-rating is justified.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Thin EBIT
- •Interest Burden
NEOG has strong liquidity and cash generation, but thin EBIT, heavy interest burden, and persistent losses keep the investment case risky despite solid margins.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Breakout pause
- •Volatile rally
NEOG has trended higher over the last month and is consolidating just below resistance at $11.90–$12.04, with support holding at $11.30–$11.40; a clean breakout above resistance would confirm renewed upside.
Sharp jump from $9.40 to $12.04 in late
Sentiment & News
Key News Insights:
- •Earnings Beat
- •Growth Momentum
- •Mixed Positioning
Neogen beat fiscal Q4 revenue and earnings, posted its strongest core growth of FY2026, raised FY2027 spending and guidance, and saw mixed institutional moves as investors balance improving momentum with valuation.
The news is modestly positive for Neogen as stronger operating trends and updated guidance support the stock, though valuation and investor caution may limit near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings